What is Elegen?
Elegen is at the forefront of the synthetic biology revolution, developing groundbreaking technologies to enable DNA writing with unprecedented speed, cost, and quality. The company aims to unlock the power to reprogram biology, creating biologic solutions to address some of humanity's most pressing challenges. This focus on advanced DNA synthesis positions Elegen as a key enabler for a new era of biological innovation, impacting diverse fields from medicine to materials science.
How much funding has Elegen raised?
Elegen has raised a total of $35M across 1 funding round:
Series B
$35M
Series B (2024): $35M with participation from GSK
Key Investors in Elegen
GSK
GSK plc is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines and vaccines. Their investment in Elegen suggests a strategic interest in synthetic biology applications for therapeutic development, particularly in areas like oncology, immunology, and infectious diseases.
What's next for Elegen?
With this major enterprise-level funding, Elegen is poised to accelerate its research and development efforts, scale its technological capabilities, and expand its market reach. The strategic investment signals strong confidence in Elegen's vision and its potential to lead in the synthetic biology space. Future growth will likely involve further technological advancements, strategic partnerships, and the commercialization of its DNA writing platforms to catalyze widespread adoption across various industries.
See full Elegen company page
